Bioprocessing
ERS Genomics inks licensing agreement with Applied StemCell
ERS Genomics said that it has signed a licensing agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents.
Bristol Myers Squibb licenses cell therapy candidate from Obsidian
Bristol Myers Squibb has exercised an option to an exclusive worldwide license to a cell therapy candidate based on Obsidian Therapeutics' cytoDrive technology.
Thermo Fisher expands plastics production to support COVID-19 efforts
Thermo Fisher Scientific is investing an additional $140 million to further expand its laboratory plastics consumables production to support the global need for COVID-19 testing, development, and manufacturing of therapies and vaccines.
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic.  Discuss
Thermo Fisher center forms partnerships for biomarkers
Thermo Fisher Scientific announced new collaborations for clinical biomarker discovery among the Thermo Fisher Precision Medicine Science Center, AstraZeneca, and the University of Nebraska Medical Center.
GlycoT Therapeutics licenses glycoengineering tech to Daiichi Sankyo
GlycoT Therapeutics has signed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo.
Neogene Therapeutics to develop personalized cell therapies
Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series A financing.
Harbour BioMed, Hualan Genetic partner on antibody programs
Harbour BioMed and Hualan Genetic Engineering have entered a strategic partnership agreement to develop three proprietary monoclonal and bispecific antibodies from Harbour's portfolio.
Curi Bio launches ComboMat to aid preclinical drug development
Curi Bio released its new proprietary ComboMat platform, a human induced pluripotent stem cell cardiomyocyte maturation technology with applications in drug discovery, disease modeling, and safety and efficacy screening.
Integral Molecular adds to its antibody discovery platform
Integral Molecular has developed humanized chicken antibody technology and incorporated it into its MPS antibody discovery platform for multipass membrane proteins. The tech will allow for the isolation of fully humanized antibodies directly from immunized animals.
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter